Related Parties Transactions - Schedule of Related Parties Transactions (Details) - USD ($) |
9 Months Ended | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 |
Dec. 31, 2025 |
Sep. 30, 2025 |
|||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due from related party- Current | $ 1,934,197 | ||||||||||||||||||||||
| Due to related parties | 1,236,996 | ||||||||||||||||||||||
| Previously Reported [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due from related party- Current | 2,694,743 | ||||||||||||||||||||||
| Due to related parties | 1,201,592 | ||||||||||||||||||||||
| Revision of Prior Period, Adjustment [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due from related party- Current | (760,546) | ||||||||||||||||||||||
| Due to related parties | 35,404 | ||||||||||||||||||||||
| BioFirst [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due from related party- Current | [1] | $ 934,111 | $ 1,521,017 | ||||||||||||||||||||
| BioFirst [Member] | Previously Reported [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due from related party- Current | 761,017 | ||||||||||||||||||||||
| BioFirst [Member] | Revision of Prior Period, Adjustment [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due from related party- Current | 760,000 | ||||||||||||||||||||||
| Rgene [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due from related party- Current | [2] | 2,347 | [1] | ||||||||||||||||||||
| Rgene [Member] | Previously Reported [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due from related party- Current | 2,347 | ||||||||||||||||||||||
| Rgene [Member] | Revision of Prior Period, Adjustment [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due from related party- Current | |||||||||||||||||||||||
| Director [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due from related party- Current | [3] | 24 | [1] | ||||||||||||||||||||
| Director [Member] | Previously Reported [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due from related party- Current | 24 | ||||||||||||||||||||||
| Director [Member] | Revision of Prior Period, Adjustment [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due from related party- Current | |||||||||||||||||||||||
| Related Party [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due from related party- Current | 934,111 | 1,523,388 | [4] | ||||||||||||||||||||
| Due from related parties- Non-current, net | 963,740 | 960,193 | |||||||||||||||||||||
| Less: allowance for expected credit losses accounts | (963,740) | (960,193) | |||||||||||||||||||||
| Net | |||||||||||||||||||||||
| Due to related parties | 1,478,178 | 865,704 | [4] | ||||||||||||||||||||
| Related Party [Member] | Previously Reported [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due from related party- Current | 763,388 | ||||||||||||||||||||||
| Due to related parties | 105,704 | ||||||||||||||||||||||
| Related Party [Member] | Revision of Prior Period, Adjustment [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due from related party- Current | 760,000 | ||||||||||||||||||||||
| Due to related parties | 760,000 | ||||||||||||||||||||||
| BioFirst (Australia) [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due from related parties- Non-current, net | [5] | 839,983 | 839,983 | ||||||||||||||||||||
| BioHopeKing Corporation [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due from related parties- Non-current, net | [6] | 123,757 | 120,210 | ||||||||||||||||||||
| The Jiangs [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due to related parties | [7] | 631,531 | 300 | [8] | |||||||||||||||||||
| The Jiangs [Member] | Previously Reported [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due to related parties | 300 | ||||||||||||||||||||||
| The Jiangs [Member] | Revision of Prior Period, Adjustment [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due to related parties | |||||||||||||||||||||||
| Shareholders and Subsidiaries' management [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due to related parties | [9] | 57,759 | [8] | ||||||||||||||||||||
| ForSeeCon [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due to related parties | 200,000 | [8] | 270,000 | [8] | 200,000 | ||||||||||||||||||
| ForSeeCon [Member] | Previously Reported [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due to related parties | 70,000 | ||||||||||||||||||||||
| ForSeeCon [Member] | Revision of Prior Period, Adjustment [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due to related parties | 200,000 | ||||||||||||||||||||||
| OncoX [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due to related parties | 560,000 | [8] | 595,404 | [8] | $ 560,000 | ||||||||||||||||||
| OncoX [Member] | Previously Reported [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due to related parties | 35,404 | ||||||||||||||||||||||
| OncoX [Member] | Revision of Prior Period, Adjustment [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due to related parties | 560,000 | ||||||||||||||||||||||
| Lion Art [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Due to related parties | $ 28,888 | [8] | |||||||||||||||||||||
| BioFirst Corporation (the "BioFirst") [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Relationship with the Company and its subsidiaries | Entity controlled by controlling beneficiary shareholder of YuanGene | ||||||||||||||||||||||
| BioFirst (Australia) Pty Ltd. (the “BioFirst (Australia)”) [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Relationship with the Company and its subsidiaries | 100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene | ||||||||||||||||||||||
| Rgene Corporation (the “Rgene”) [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Relationship with the Company and its subsidiaries | Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene; the Chairman of Rgene is Mr. Tsung-Shann Jiang | ||||||||||||||||||||||
| GenePharm Inc. (the “GenePharm”) [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Relationship with the Company and its subsidiaries | Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm. | ||||||||||||||||||||||
| The Jiangs [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Relationship with the Company and its subsidiaries | Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirstMs. Shuling Jiang, is the Chairman of Keypoint; and a member of board of directors of the Company and BioLite Inc, and a member of board of directors of BioFirst; a director and beneficial owner of more than 10% of the ABVC’s outstanding common stockMr. Eugene Jiang is Mr. and Ms. Jiang’s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc. Mr. Eugene Jiang is a member of board of directors of BioFirst.Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang’s sibling and the director of the Company, and a member of board of directors of BioFirst.Ms. Mei-Ling Jiang is Ms. Shuling Jiang’s sibling. | ||||||||||||||||||||||
| BioLite Japan [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Relationship with the Company and its subsidiaries | Entity controlled by controlling beneficiary shareholder of ABVC | ||||||||||||||||||||||
| BioHopeKing Corporation (“BHK”) [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Relationship with the Company and its subsidiaries | Entity controlled by controlling beneficiary shareholder of ABVC | ||||||||||||||||||||||
| AiBtl (Holding) BioPharma, Inc. (“AiBtl Holding”) [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Relationship with the Company and its subsidiaries | Founding shareholder of AiBtl BioPharma Inc. | ||||||||||||||||||||||
| Jaimes Vargas Russman [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Relationship with the Company and its subsidiaries | CEO of AiBtl BioPharma Inc. | ||||||||||||||||||||||
| Lion Arts Promotion, Inc. (“Lion Arts”) [Member] | |||||||||||||||||||||||
| Schedule of Related Parties Transactions [Line Items] | |||||||||||||||||||||||
| Relationship with the Company and its subsidiaries | Entity controlled by the Jiangs. | ||||||||||||||||||||||
| |||||||||||||||||||||||